Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility

Legacy Context: From General Health to Occupational Risk

The legacy context of general health and science information has long emphasized the importance of understanding how environmental and pharmaceutical exposures may influence disease risk. Within this broad framework, public health communication has historically focused on educating populations about potential hazards, from lifestyle factors to therapeutic interventions. This foundational approach provides a structured lens for examining emerging concerns in occupational settings, where workers may encounter substances not typically present in general populations. Transitioning from this general health heritage, the focus narrows to occupational exposure scenarios involving pharmaceutical agents. In mass production environments, workers may handle active compounds during manufacturing, packaging, or quality control processes. One such compound is Avelumab, a monoclonal antibody used in oncology. While its therapeutic applications are well-documented, the potential for occupational exposure raises questions about long-term health risks, including the possibility of carcinogenic effects. Specifically, the biological plausibility of Avelumab-related Merkel Cell Carcinoma causation warrants careful examination, as workers in production facilities may face repeated, low-level contact with the drug. This shift from general health education to occupational risk assessment underscores the need for targeted surveillance and protective measures in industrial settings, where exposure patterns differ markedly from clinical or environmental contexts.

Bridge: Understanding Avelumab's Mechanism and Indication

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, which demonstrated confirmed objective responses in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the relationship between avelumab and MCC causation requires careful examination of biological plausibility, risk communication, and temporal considerations.

Biological Plausibility: Does Avelumab Cause MCC?

MCC has two primary etiologies: approximately 80% of cases are caused by the Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by ultraviolet light, leading to a high mutational burden (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to recognize and attack tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). This mechanism is therapeutically beneficial for treating existing MCC, but it does not provide a direct pathway for causing MCC. Instead, avelumab is associated with immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids and allowed continuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). While irAEs can affect various organs, there is no evidence in the provided sources that avelumab directly induces de novo MCC. The biological plausibility of avelumab causing MCC is therefore low, as the drug is designed to treat MCC by enhancing immune surveillance, not to initiate carcinogenesis.

Risk Communication and Warnings

The adequacy of warnings regarding avelumab and MCC is informed by the drug's approved indication. Avelumab is specifically approved for the treatment of metastatic MCC, meaning that patients receiving the drug already have a diagnosis of MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The primary risk associated with avelumab in this context is not causation of MCC but rather lack of response or development of irAEs. Studies indicate that up to 50% of patients do not respond to immune checkpoint inhibitors or develop irAEs due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab have shown efficacy, with three out of five patients in one study responding according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study reported response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). These data suggest that warnings should focus on the potential for treatment failure and irAEs rather than on MCC causation, as the drug is used in patients who already have the disease.

Causation Considerations for Affected Patients

For patients who develop new or worsening MCC while on avelumab, causation is complex. Since avelumab is indicated for existing MCC, any progression of disease is more likely attributable to the natural history of the cancer or treatment resistance rather than a drug-induced effect. The provided evidence does not support a causal link between avelumab and the initiation of MCC. Instead, the drug's role is therapeutic, and its use is associated with improved overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). Patients who experience progression on avelumab may have tumors that are inherently resistant due to viral or UV-induced mechanisms (https://pubmed.ncbi.nlm.nih.gov/34445385/). Therefore, causation considerations should emphasize that avelumab is not known to cause MCC, but rather is used to treat it, and that progression reflects tumor biology or immune evasion.

Timeline Between Exposure and Documented Harm

The timeline between avelumab exposure and harm is typically measured in weeks to months, as irAEs can occur during treatment. For example, the case of hypercalcemia due to sarcoidosis reactivation occurred during avelumab therapy and resolved with corticosteroids, allowing continued treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/). In terms of MCC progression, the JAVELIN Merkel 200 trial evaluated responses in chemotherapy-refractory patients, indicating that harm (lack of response or progression) can be assessed within the trial's follow-up period (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, there is no evidence of a delayed carcinogenic effect leading to new MCC after avelumab exposure. The timeline for harm is thus confined to the treatment period and is related to therapeutic failure or irAEs, not to drug-induced carcinogenesis. In summary, the evidence does not support a biological plausible mechanism for avelumab causing MCC. The drug is an established treatment for MCC, and its risks are primarily related to immune-related adverse events and treatment resistance. Warnings should address these risks rather than causation, and patients should be monitored for progression and irAEs during therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel Cell Carcinoma?

No, the evidence does not support a causal link. Avelumab is an immune checkpoint inhibitor used to treat existing Merkel Cell Carcinoma (MCC) by enhancing the immune response against tumor cells. Its mechanism does not initiate carcinogenesis, and no studies have shown that it induces de novo MCC. The primary risks are treatment failure and immune-related adverse events.

What are the risks of Avelumab therapy?

The main risks include lack of response (up to 50% of patients) and immune-related adverse events (irAEs) such as hypercalcemia from sarcoidosis reactivation. These can occur weeks to months after starting treatment. Avelumab is not associated with causing new cancers; its approved use is for patients already diagnosed with MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.